A distinct pattern in the changing length of blood telomeres, the protective end caps on our DNA strands, can predict cancer many years before actual diagnosis, according to a new study from Northwestern Medicine in collaboration with Harvard University.
The pattern – a rapid shortening followed by a stabilization three or four years before cancer is diagnosed – could ultimately yield a new biomarker to predict cancer development with a blood test. This is the first reported trajectory of telomere changes over the years in people developing cancer.
Scientists have been trying to understand how blood cell telomeres, considered a marker of biological age, are affected in people who are developing cancer. But the results have been inconsistent: some studies find they are shorter, some longer and some show no correlation at all.
The Northwestern and Harvard study shows why previous results were confusing.
In the new study, scientists took multiple measurements of telomeres over a 13-year period in 792 persons, 135 of whom were eventually diagnosed with different types of cancer, including prostate, skin, lung, leukemia and others.
Initially, scientists discovered telomeres aged much faster (indicated by a more rapid loss of length) in individuals who were developing but not yet diagnosed with cancer. Telomeres in persons developing cancer looked as much as 15 years chronologically older than those of people who were not developing the disease.
But then scientists found the accelerated aging process stopped three to four years before the cancer diagnosis.
“Understanding this pattern of telomere growth may mean it can be a predictive biomarker for cancer,” said Dr. Lifang Hou, the lead study author and faculty member at the Institute for Public Health and Medicine-Center for Population Health Sciences. “Because we saw a strong relationship in the pattern across a wide variety of cancers, with the right testing these procedures could be used to eventually diagnose a wide variety of cancers.” Dr. Hou also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
The Northwestern and Harvard study is believed to be the first to look at telomere length at more than one time point before diagnosis. That’s significant because cancer treatment can shorten telomeres. Post treatment, it’s uncertain whether their length has been affected by the cancer or the treatment.
The research was supported by grants R01ES021733 and R01ES015172 from the National Institute of Environmental Health Sciences of the National Institutes of Health.
See journal article: http://www.sciencedirect.com/science/article/pii/S2352396415001024